Megacystis at 10-14 weeks of gestation: chromosomal defects and outcome according to bladder length

A W Liao1, N J Sebire, L Geerts

  • 1Harris Birthright Research Centre for Fetal Medicine, King's College Hospital Medical School, London, UK.

Insights

Fetal megacystis, a bladder enlargement, has a 25% risk of chromosomal defects when measuring 7-15 mm. In normal karyotypes, 90% resolve spontaneously, but larger diameters indicate poor outcomes.

Area of Science:

  • Prenatal diagnosis
  • Fetal medicine
  • Medical genetics

Background:

  • Fetal megacystis, defined as a longitudinal bladder diameter of 7 mm or more at 10-14 weeks gestation, is a condition requiring careful evaluation.
  • Understanding the association between fetal megacystis size and chromosomal abnormalities is crucial for accurate prognosis.

Purpose of the Study:

  • To determine the prevalence of chromosomal defects in fetuses with megacystis.
  • To analyze the pregnancy outcomes in relation to fetal bladder size and karyotype.

Main Methods:

  • A cohort of 145 fetuses with megacystis (longitudinal bladder diameter ≥ 7 mm) at 10-14 weeks gestation were studied.
  • Fetal karyotype and pregnancy outcomes were assessed, correlating with the longitudinal bladder diameter.

Main Results:

  • Chromosomal defects, primarily trisomies 13 and 18, were found in 30 cases.
  • A bladder diameter of 7-15 mm showed a 23.6% incidence of chromosomal defects, while >15 mm had an 11.4% incidence.
  • Spontaneous resolution occurred in 90% of chromosomally normal fetuses with 7-15 mm bladder diameter; none resolved if >15 mm.

Conclusions:

  • Fetal megacystis measuring 7-15 mm carries a ~25% risk of chromosomal defects, with spontaneous resolution in ~90% of normal karyotypes.
  • Bladder diameters >15 mm indicate a ~10% risk of chromosomal defects and are invariably linked to progressive obstructive uropathy in chromosomally normal fetuses.
Abstract

Related Concept Videos

Imaging Studies VI: Voiding Cystourethrography and Cystography01:22

Imaging Studies VI: Voiding Cystourethrography and Cystography

Voiding Cystourethrography (VCUG) and Cystography are specialized radiographic procedures used to examine the structure and function of the bladder and urethra.Voiding Cystourethrography (VCUG)A Voiding Cystourethrogram (VCUG) is a diagnostic imaging procedure that assesses the anatomy and function of the lower urinary tract. It focuses on the bladder, bladder neck, and urethra, helping detect abnormalities such as vesicoureteral reflux (VUR)—the backward or reverse flow of urine into the...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Urinary Bladder01:23

Urinary Bladder

The urinary bladder is a hollow, muscular sac that temporarily stores urine before it is expelled from the body. It can hold approximately 600 mL of urine prior to micturition. The bladder is retroperitoneal and located behind the pubic symphysis in the pelvic floor.
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...